Search

Your search keyword '"van Imhoff, Gustaaf W."' showing total 287 results
Start Over Author "van Imhoff, Gustaaf W."
287 results on '"van Imhoff, Gustaaf W."'

1. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

Author

Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, and Lugtenburg, Pieternella

Published
2023
Full Text
View/download PDF

3. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Author

Fermé, Christophe, Thomas, José, Brice, Pauline, Casasnovas, Olivier, Vranovsky, Andrej, Bologna, Serge, Lugtenburg, Pieternella J., Bouabdallah, Réda, Carde, Patrice, Sebban, Catherine, Eghbali, Houchingue, Salles, Gilles, van Imhoff, Gustaaf W., Thyss, Antoine, Noordijk, Evert M., Reman, Oumédaly, Lybeert, Marnix L.M., Janvier, Maud, Spina, Michele, Audhuy, Bruno, Raemaekers, John M.M., Delarue, Richard, Anglaret, Bruno, de Weerdt, Okke, Marjanovic, Zora, Tersteeg, Robbert J.H.A., de Jong, Daphne, Brière, Josette, and Henry-Amar, Michel

Published
2017
Full Text
View/download PDF

4. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, Lugtenburg, Pieternella, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, and Lugtenburg, Pieternella

Published
2023

7. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Author

Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)

Subjects
0301 basic medicine, Male, cd52 expression, Cancer Research, epstein-barr-virus, medicine.medical_treatment, CHOP, Gastroenterology, PROPHYLAXIS, 0302 clinical medicine, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Significant risk, Alemtuzumab, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Hematology, lymphoproliferative disorders, Hazard ratio, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, 3. Good health, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, Toxicity, PHASE-II, Female, medicine.drug, medicine.medical_specialty, prognostic-factors, Medication Adherence, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, non-hodgkin-lymphoma, Cyclophosphamide, Aged, Chemotherapy, therapy, business.industry, Lymphoma, T-Cell, Peripheral, DETUDE-DES-LYMPHOMES, medicine.disease, Survival Analysis, Peripheral T-cell lymphoma, 030104 developmental biology, Doxorubicin, Prednisone, business
Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Published
2021
Full Text
View/download PDF

9. Double-hit B-cell lymphomas

Author

Aukema, Sietse M., Siebert, Reiner, Schuuring, Ed, van Imhoff, Gustaaf W., Kluin-Nelemans, Hanneke C., Boerma, Evert-Jan, and Kluin, Philip M.

Published
2011
Full Text
View/download PDF

11. Second Cancer Risk Up to 40 Years after Treatment for Hodgkinʼs Lymphoma

Author

Schaapveld, Michael, Aleman, Berthe M.P., van Eggermond, Anna M., Janus, Cécile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Raemaekers, John M.M., de Boer, Jan Paul, Zijlstra, Josée M., van Imhoff, Gustaaf W., Petersen, Eefke J., Poortmans, Philip M.P., Beijert, Max, Lybeert, Marnix L., Mulder, Ina, Visser, Otto, Louwman, Marieke W.J., Krul, Inge M., Lugtenburg, Pieternella J., and van Leeuwen, Flora E.

Published
2015
Full Text
View/download PDF

13. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT)

Author

Poiré, Xavier, Labopin, Myriam, Cornelissen, Jan J., Volin, Liisa, Richard Espiga, Carlos, Veelken, Hendrik J., Milpied, Noël, Cahn, Jean-Yves, Yacoub-Agha, Ibrahim, van Imhoff, Gustaaf W., Michallet, Mauricette, Michaux, Lucienne, Nagler, Arnon, and Mohty, Mohamad

Published
2015
Full Text
View/download PDF

14. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Author

UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, and ACT-2 study investigators

Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61-80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%-39%], 28% [15%-40%], and 37% ([23%-50%] for A-CHOP, and 24% [12%-35%], 29% [17%-41%], and 56% [44%-69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HR: 0.7 ([95% CI: 0.5-1.1]; p = 0.094), HR: 0.8 ([95% CI: 0.5-1.2]; p = 0.271), HR: 1.4 ([95% CI: 0.9-2.4]; p = 0.154). The IPI score was validated, and male sex (HR 2.5) and bulky disease (HR 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Published
2021

15. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients

Author

de Vries, Simone, Schaapveld, Michael, Janus, Cécile P.M., Daniëls, Laurien A., Petersen, Eefke J., van der Maazen, Richard W.M., Zijlstra, Josée M., Beijert, Max, Nijziel, Marten R., Verschueren, Karijn M.S., Kremer, Leontien C.M., van Eggermond, Anna M., Lugtenburg, Pieternella J., Krol, Augustinus D.G., Roesink, Judith M., Plattel, Wouter J., van Spronsen, Dick Johan, van Imhoff, Gustaaf W., de Boer, Jan Paul, Aleman, Berthe M.P., van Leeuwen, Flora E., de Vries, Simone, Schaapveld, Michael, Janus, Cécile P.M., Daniëls, Laurien A., Petersen, Eefke J., van der Maazen, Richard W.M., Zijlstra, Josée M., Beijert, Max, Nijziel, Marten R., Verschueren, Karijn M.S., Kremer, Leontien C.M., van Eggermond, Anna M., Lugtenburg, Pieternella J., Krol, Augustinus D.G., Roesink, Judith M., Plattel, Wouter J., van Spronsen, Dick Johan, van Imhoff, Gustaaf W., de Boer, Jan Paul, Aleman, Berthe M.P., and van Leeuwen, Flora E.

Abstract

BACKGROUND: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients. METHODS: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated. RESULTS: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes other than HL. This risk remained increased in 40-year survivors (standardized mortality ratio = 5.2, 95% confidence interval [CI] = 4.2 to 6.5, AEM = 619). At age 54 years, HL survivors experienced similar cumulative mortality (20.0%) from causes other than HL to 71-year-old individuals from the general population. Whereas HL mortality statistically significantly decreased over the calendar period (P < .001), solid tumor mortality did not change in the most recent treatment era. Patients treated in 1989-2000 had lower 25-year cardiovascular disease mortality than patients treated in 1965-1976 (4.3% vs 5.7%; subdistribution hazard ratio = 0.65, 95% CI = 0.46 to 0.93). Infectious disease mortality was not only increased after splenectomy but also after spleen irradiation (hazard ratio = 2.81, 95% CI = 1.55 to 5.07). For stage I-II, primary treatment with chemotherapy (CT) alone was associated with statistically significantly higher HL mortality (P < .001 for CT vs radiotherapy [RT]; P = .04 for CT vs RT+CT) but lower 30-year mortality from causes other than HL (15.8%, 95% CI = 9.7% to 23.3%) compared with RT alone (36.9%, 95% CI = 34.0% to 39.8%, P = .001) and RT and CT combined (29.8%, 95% CI = 26.8% to 32.9%, P = .02). CONCLUSIONS: Compared with the general population, HL survivors have a su

Published
2021

16. Long-term cause-specific mortality in hodgkin lymphoma patients

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, van Leeuwen, Flora E, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2021

18. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide:II HOVON trial results of a multicenter

Author

Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, and Kersten, Marie José

Abstract

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).

Published
2020
Full Text
View/download PDF

19. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide: II HOVON trial results of a multicenter

Author

Chamuleau, Martine E. D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S. P., Marijt, Eric A. F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J. F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I. J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, Kersten, Marie José, Hematology, CCA - Cancer Treatment and quality of life, Internal medicine, Oral and Maxillofacial Surgery / Oral Pathology, Pathology, Radiology and nuclear medicine, CCA - Imaging and biomarkers, AGEM - Re-generation and cancer of the digestive system, AII - Cancer immunology, Erasmus MC other, Radiotherapy, Clinical Haematology, and CCA - Cancer Treatment and Quality of Life

Abstract

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).

Published
2020

20. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial: II HOVON trial results of a multicenter

Author

Stamceltransplantatieteam, MS Hematologie, Infection & Immunity, Cancer, Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, Kersten, Marie José, Stamceltransplantatieteam, MS Hematologie, Infection & Immunity, Cancer, Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, and Kersten, Marie José

Published
2020

24. Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined Subgroups

Author

Urayama, Kevin Y., Jarrett, Ruth F., Hjalgrim, Henrik, Diepstra, Arjan, Kamatani, Yoichiro, Chabrier, Amelie, Gaborieau, Valerie, Boland, Anne, Nieters, Alexandra, Becker, Nikolaus, Foretova, Lenka, Benavente, Yolanda, Maynadié, Marc, Staines, Anthony, Shield, Lesley, Lake, Annette, Montgomery, Dorothy, Taylor, Malcolm, Smedby, Karin Ekström, Amini, Rose-Marie, Adami, Hans-Olov, Glimelius, Bengt, Feenstra, Bjarke, Nolte, Ilja M., Visser, Lydia, van Imhoff, Gustaaf W., Lightfoot, Tracy, Cocco, Pierluigi, Kiemeney, Lambertus, Vermeulen, Sita H., Holcatova, Ivana, Vatten, Lars, Macfarlane, Gary J., Thomson, Peter, Conway, David I., Benhamou, Simone, Agudo, Antonio, Healy, Claire M., Overvad, Kim, Tjønneland, Anne, Melin, Beatrice, Canzian, Federico, Khaw, Kay-Tee, Travis, Ruth C., Peeters, Petra H. M., González, Carlos A., Quirós, José Ramón, Sánchez, María-José, Huerta, José María, Ardanaz, Eva, Dorronsoro, Miren, Clavel-Chapelon, Françoise, Bueno-de-Mesquita, H. Bas, Riboli, Elio, Roman, Eve, Boffetta, Paolo, de Sanjosé, Silvia, Zelenika, Diana, Melbye, Mads, van den Berg, Anke, Lathrop, Mark, Brennan, Paul, and McKay, James D.

Published
2012
Full Text
View/download PDF

25. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients

Author

de Vries, Simone, primary, Schaapveld, Michael, additional, Janus, Cécile P M, additional, Daniëls, Laurien A, additional, Petersen, Eefke J, additional, van der Maazen, Richard W M, additional, Zijlstra, Josée M, additional, Beijert, Max, additional, Nijziel, Marten R, additional, Verschueren, Karijn M S, additional, Kremer, Leontien C M, additional, van Eggermond, Anna M, additional, Lugtenburg, Pieternella J, additional, Krol, Augustinus D G, additional, Roesink, Judith M, additional, Plattel, Wouter J, additional, van Spronsen, Dick Johan, additional, van Imhoff, Gustaaf W, additional, de Boer, Jan Paul, additional, Aleman, Berthe M P, additional, and van Leeuwen, Flora E, additional

Published
2020
Full Text
View/download PDF

27. Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study

Author

Lugtenburg, Pieternella J, Zijlstra, Josee M, Doorduijn, Jeanette K, Böhmer, Lara H, Hoogendoorn, Mels, Berenschot, Henriette W, Beeker, Aart, van der Burg-de Graauw, Nicole C, Schouten, Harry C, Bilgin, Yavuz M, Kersten, Marie-Jose, Koene, Harry R, Herbers, Alexandra H E, de Jong, Daphne, Hijmering, Nathalie, Lam, King H, Chiţu, Dana, Brouwer, Rolf E, van Imhoff, Gustaaf W, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Hematology, and Pathology

Subjects
relapse, PLUS RITUXIMAB, IBRITUMOMAB TIUXETAN, diffuse large B-cell lymphoma, MULTICENTER, B-CELL LYMPHOMA, PECC, CHEMOTHERAPY, OPEN-LABEL, TRIAL, Y-90-ibritumomab tiuxetan, COMBINATION, consolidation, ELDERLY-PATIENTS, CHOP
Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with Y-90-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade >= 3 adverse events from start of Y-90-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to Y-90-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after Y-90-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of Y-90-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33-68%) and 62% (95% CI, 42-77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17-39%) and 49% (95% CI, 36-61%), respectively. Toxicities of R-PECC and Y-90-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with Y-90-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019

28. Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Author

Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Bohmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg-de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie-Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chitu, Dana, Brouwer, Rolf E., and van Imhoff, Gustaaf W.

Subjects
relapse, PLUS RITUXIMAB, IBRITUMOMAB TIUXETAN, diffuse large B-cell lymphoma, MULTICENTER, B-CELL LYMPHOMA, PECC, CHEMOTHERAPY, OPEN-LABEL, TRIAL, Y-90-ibritumomab tiuxetan, COMBINATION, consolidation, ELDERLY-PATIENTS, CHOP
Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with Y-90-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade >= 3 adverse events from start of Y-90-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to Y-90-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after Y-90-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of Y-90-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33-68%) and 62% (95% CI, 42-77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17-39%) and 49% (95% CI, 36-61%), respectively. Toxicities of R-PECC and Y-90-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with Y-90-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019

29. Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Author

Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg-de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie-Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., van Imhoff, Gustaaf W., Hematology, CCA - Cancer Treatment and quality of life, Pathology, AGEM - Re-generation and cancer of the digestive system, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, CCA - Cancer Treatment and Quality of Life, and Clinical Haematology

Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with 90Y-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade ≥3 adverse events from start of 90Y-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to 90Y-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after 90Y-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of 90Y-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33–68%) and 62% (95% CI, 42–77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17–39%) and 49% (95% CI, 36–61%), respectively. Toxicities of R-PECC and 90Y-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with 90Y-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019
Full Text
View/download PDF

34. Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkinʼs Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40

Author

van Imhoff, Gustaaf W., van der Holt, Bronno, MacKenzie, Marius A., vanʼt Veer, Mars B., Wijermans, Pierre W., Ossenkoppele, Gerrit J., Schouten, Harry C., Sonneveld, Pieter, Steijaert, Monique M.C., Kluin, Philip M., Kluin-Nelemans, Hanneke C., and Verdonck, Leo F.

Published
2005
Full Text
View/download PDF

36. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Author

Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., van Leerdam, Monique E., Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

37. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Author

Cancer, MS Radiotherapie, Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., van Leerdam, Monique E., Cancer, MS Radiotherapie, Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

40. Role of echocardiography in the diagnosis of cardiac lymphoma

Author

Van Veldhuisen, Dirk J., Hamer, Hans P.M., Van Imhoff, Gustaaf W., Hollema, Harry, and Lie, Kong I.

Subjects
Lymphomas -- Diagnosis, Echocardiography -- Evaluation, Lymphomas -- Case studies, Health
Abstract

Lymphoma (cancer of cells of the lymphatic drainage system) can affect many body tissues and organs, including the heart, where it is found in up to 25 percent of patients. However, cardiac lymphoma is rarely diagnosed before death. Echocardiography, which uses ultrasound, has been useful in detection of several types of heart tumors. Four cases of echocardiographic detection of cardiac lymphoma are described in this article. Tumors were found in the right atria (upper heart chambers) in all four patients, with spreading to the left atrium in one patient. Pericardial effusion, in which fluid had escaped into the sac surrounding the heart, was present in three patients. Placement of the ultrasound probe in the esophagus (transesophageal echocardiography) was very useful in tumor detection. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

44. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: Results of the HOVON 80 phase 2 study

Author

Doorduijn, Jeanette K., van Imhoff, Gustaaf W., van der Holt, Bronno, Schouten, Harry C., Schaafsma, Martijn R., MacKenzie, Marius A., Baars, Joke W., Kersten, Marie José, Lugtenburg, Pieternella J., van den Bent, Martin J., Enting, Roelien H., Spoelstra, Fokje M., Poortmans, Philip, Bromberg, Jacoline E. C., Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Hematologie (9), Interne Geneeskunde, CCA - Cancer Treatment and Quality of Life, Clinical Haematology, and Cancer Center Amsterdam

Subjects
treatment, AGGRESSIVE LYMPHOMA, MABTHERA INTERNATIONAL TRIAL, clinical trial, methotrexate, STUDY-GROUP DSHNHL, INTRAOCULAR LYMPHOMA, rituximab, PRIMARY CNS LYMPHOMA, NON-HODGKINS-LYMPHOMA, CHEMOTHERAPY PLUS RITUXIMAB, MARROW-TRANSPLANTATION, ELDERLY-PATIENTS, secondary CNS lymphoma, transplantation, RESPONSE CRITERIA
Abstract

The prognosis of central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma is poor with 1-year survival historically at 0% to 20%. Aiming to improve these results, we performed a multicenter phase 2 study in patients with a CNS relapse, with or without concurrent systemic relapse. Treatment consisted of 2 cycles of R-DHAP alternating with high-dose methotrexate (MTX) and was combined with intrathecal rituximab. Responding patients received a third R-DHAP-MTX cycle followed by busulfan and cyclophosphamide myeloablative therapy and autologous stem cell transplantation. In patients with persistent cerebrospinal fluid lymphoma after cycle 1, the intrathecal rituximab was replaced by intrathecal triple therapy, with MTX, cytarabine, and dexamethasone. Thirty-six patients were included. Eighteen had evidence of cerebrospinal fluid lymphoma, 24 had brain parenchymal disease, and 20 (56%) had concurrent systemic disease. The overall response rate after 2 R-DHAP-MTX was 53% (19/36), with 22% (8/36) complete remission. Fifteen patients (42%) underwent a transplant. One-year progression-free survival was 19% (95% confidence interval, 9-34): 25% in patients without and 15% in patients with systemic disease. One-year overall survival was 25% (95% confidence interval, 12-40). This treatment regimen did not result in a major improvement of outcome of secondary CNS lymphoma, especially when concurrent systemic disease was present. Registered in the Dutch trial register www. trialregister.nl, NTR1757; EudraCT number 2006-002141-37.

Published
2017

45. Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Author

Rigter, Lisanne S., primary, Schaapveld, Michael, additional, Janus, Cecile P. M., additional, Krol, Augustinus D. G., additional, van der Maazen, Richard W. M., additional, Roesink, Judith, additional, Zijlstra, Josee M., additional, van Imhoff, Gustaaf W., additional, Poortmans, Philip M. P., additional, Beijert, Max, additional, Lugtenburg, Pieternella J., additional, Visser, Otto, additional, Snaebjornsson, Petur, additional, van Eggermond, Anna M., additional, Aleman, Berthe M. P., additional, van Leeuwen, Flora E., additional, and van Leerdam, Monique E., additional

Published
2018
Full Text
View/download PDF

46. MYC Rearrangement Positive Large B-Cell Lymphoma Patients Can Be Treated Successfully with R-CHOP Plus Lenalidomide: Results of a Multicentre Phase II HOVON Trial

Author

Chamuleau, Martine, primary, Burggraaff, Coreline N., additional, Nijland, Marcel, additional, Bakunina, Katerina, additional, Mous, Rogier, additional, Lugtenburg, Pieternella J., additional, Dierickx, Daan, additional, van Imhoff, Gustaaf W., additional, Vermaat, Joost S.P., additional, Marijt, Eric A.F., additional, Visser, Otto, additional, Mandigers, Caroline, additional, Bilgin, Yavuz M., additional, Diepstra, Arjan, additional, Arens, Anne I.J., additional, Hoekstra, Otto, additional, Zijlstra, Josee M., additional, de Jong, Daphne, additional, and Kersten, Marie José, additional

Published
2018
Full Text
View/download PDF

47. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Author

Externen Hematologie, Other research (not in main researchprogram), UMC Utrecht, MS Radiotherapie, Cancer, Fermé, Christophe, Thomas, José, Brice, Pauline, Casasnovas, Olivier, Vranovsky, Andrej, Bologna, Serge, Lugtenburg, Pieternella J, Bouabdallah, Réda, Carde, Patrice, Sebban, Catherine, Eghbali, Houchingue, Salles, Gilles, Van Imhoff, Gustaaf W., Thyss, Antoine, Noordijk, Evert M., Reman, Oumédaly, Lybeert, Marnix L.M., Janvier, Maud, Spina, Michele, Audhuy, Bruno, Raemaekers, John M M, Delarue, Richard, Anglaret, Bruno, de Weerdt, Okke, Marjanovic, Zora, Tersteeg, Robbert J.H.A., de Jong, Daphne, Brière, Josette, Henry-Amar, Michel, for the European Organisation for Research and Treatment of Cancer Lymphoma Group, and, the Groupe d'Étude des Lymphomes de l'Adulte, Externen Hematologie, Other research (not in main researchprogram), UMC Utrecht, MS Radiotherapie, Cancer, Fermé, Christophe, Thomas, José, Brice, Pauline, Casasnovas, Olivier, Vranovsky, Andrej, Bologna, Serge, Lugtenburg, Pieternella J, Bouabdallah, Réda, Carde, Patrice, Sebban, Catherine, Eghbali, Houchingue, Salles, Gilles, Van Imhoff, Gustaaf W., Thyss, Antoine, Noordijk, Evert M., Reman, Oumédaly, Lybeert, Marnix L.M., Janvier, Maud, Spina, Michele, Audhuy, Bruno, Raemaekers, John M M, Delarue, Richard, Anglaret, Bruno, de Weerdt, Okke, Marjanovic, Zora, Tersteeg, Robbert J.H.A., de Jong, Daphne, Brière, Josette, Henry-Amar, Michel, for the European Organisation for Research and Treatment of Cancer Lymphoma Group, and, and the Groupe d'Étude des Lymphomes de l'Adulte

Published
2017

48. ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Author

Fermé, Christophe, primary, Thomas, José, additional, Brice, Pauline, additional, Casasnovas, Olivier, additional, Vranovsky, Andrej, additional, Bologna, Serge, additional, Lugtenburg, Pieternella J., additional, Bouabdallah, Réda, additional, Carde, Patrice, additional, Sebban, Catherine, additional, Eghbali, Houchingue, additional, Salles, Gilles, additional, van Imhoff, Gustaaf W., additional, Thyss, Antoine, additional, Noordijk, Evert M., additional, Reman, Oumédaly, additional, Lybeert, Marnix L.M., additional, Janvier, Maud, additional, Spina, Michele, additional, Audhuy, Bruno, additional, Raemaekers, John M.M., additional, Delarue, Richard, additional, Anglaret, Bruno, additional, de Weerdt, Okke, additional, Marjanovic, Zora, additional, Tersteeg, Robbert J.H.A., additional, de Jong, Daphne, additional, Brière, Josette, additional, and Henry-Amar, Michel, additional

Published
2017
Full Text
View/download PDF

50. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Author

van Imhoff, Gustaaf W., primary, McMillan, Andrew, additional, Matasar, Matthew J., additional, Radford, John, additional, Ardeshna, Kirit M., additional, Kuliczkowski, Kazimierz, additional, Kim, WonSeog, additional, Hong, Xiaonan, additional, Goerloev, Jette Soenderskov, additional, Davies, Andrew, additional, Barrigón, María Dolores Caballero, additional, Ogura, Michinori, additional, Leppä, Sirpa, additional, Fennessy, Michael, additional, Liao, Qiming, additional, van der Holt, Bronno, additional, Lisby, Steen, additional, and Hagenbeek, Anton, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results